anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban
DISEASE INTERVENTION COMPARISON RESULTS
Eur Heart J. 2013 Jul;34(27):2094-106 Consensus, Guideline
IN anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban The Use of
guidelines for their use in diverse situations in practice
As Dosage Scheme
Is useful Than
no comparison here
To optimize their use and avoid bleeding complications
Gastroenterology. 2013 Jul;145(1):105-112.e15 Systematic Review
IN anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban, edoxaban The Use of
this direct oral anticoagulants
As Treatment, Chronic
Is worse Than
warfarin
To cause a higher risk of gastrointestinal bleeding: OR 1.58 dabigatran, 1.48 rivaroxaban, 1.23 apixaban (non-significant), 0.31 edoxaban (non-significant for superiority)
J Am Geriatr Soc. 2014 May;62(5):857-64 Meta-Analysis
IN atrial fibrillation, thromboembolic disease, old patients, anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban The Use of
anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban
As Treatment, Chronic
Is better Than
warfarin
To prevent stroke or VTE recurrence: no numbers given in abstract